<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002127</url>
  </required_header>
  <id_info>
    <org_study_id>AT148006</org_study_id>
    <nct_id>NCT05002127</nct_id>
  </id_info>
  <brief_title>A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)</brief_title>
  <official_title>A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALX Oncology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ALX Oncology Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and&#xD;
      Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase 2 (open-label) / 3 (double-blind), international, multi-center&#xD;
      study of patients with metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that has&#xD;
      progressed on or after prior HER2-directed therapy and fluoropyrimidine- or&#xD;
      platinum-containing chemotherapy and are suitable for chemotherapy (2nd-line or 3rd-line).&#xD;
      Approximately 450 adult patients are expected to be enrolled in the study across both phases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2028</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Phase 2 is Open Label; Phase 3 is blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2</measure>
    <time_frame>Last randomized patient on study at least 16 weeks</time_frame>
    <description>Percentage of patients with objective response per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 3</measure>
    <time_frame>From the date of randomization to the date of death (due to any cause), up to 36 months postdose</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase 2 - Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 - Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evorpacept (ALX148) 30 mg/kg Q2W IV, trastuzumab (initial dose of 6 mg/kg followed by 4 mg/kg) Q2W IV, ramucirumab 8 mg/kg Q2W IV, and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 3 - Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramucirumab 8 mg/kg Q2W IV and paclitaxel 80 mg/m2 IV Days 1, 8, and 15 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evorpacept (ALX148)</intervention_name>
    <description>IV Q2W</description>
    <arm_group_label>Phase 2 - Arm A</arm_group_label>
    <arm_group_label>Phase 3 - Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>IV Q2W</description>
    <arm_group_label>Phase 2 - Arm A</arm_group_label>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
    <arm_group_label>Phase 3 - Arm A</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>IV Q2W</description>
    <arm_group_label>Phase 2 - Arm A</arm_group_label>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
    <arm_group_label>Phase 3 - Arm A</arm_group_label>
    <arm_group_label>Phase 3 - Arm B</arm_group_label>
    <other_name>Cyramza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV Days 1, 8, and 15 of a 28-day cycle</description>
    <arm_group_label>Phase 2 - Arm A</arm_group_label>
    <arm_group_label>Phase 2 - Arm B</arm_group_label>
    <arm_group_label>Phase 3 - Arm A</arm_group_label>
    <arm_group_label>Phase 3 - Arm B</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ)&#xD;
             adenocarcinoma that has progressed on or after a prior HER2-directed agent and&#xD;
             fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)&#xD;
&#xD;
          -  Adequate Bone Marrow Function.&#xD;
&#xD;
          -  Adequate Renal &amp; Liver Function.&#xD;
&#xD;
          -  Adequate Performance Status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known symptomatic CNS metastases or leptomeningeal disease requiring&#xD;
             steroids.&#xD;
&#xD;
          -  Prior treatment with any anti-CD47 or anti-SIRPα agent.&#xD;
&#xD;
          -  Prior treatment with ramucirumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philip Fanning, PhD</last_name>
    <phone>650-466-7125</phone>
    <email>info@alxoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophia Randolph, MD, PhD</last_name>
    <phone>650-466-7125</phone>
    <email>info@alxoncology.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALX148</keyword>
  <keyword>CD47</keyword>
  <keyword>SIRPα</keyword>
  <keyword>Gastric</keyword>
  <keyword>Gastroesophageal</keyword>
  <keyword>GEJ</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Ramucirumab</keyword>
  <keyword>Evorpacept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

